Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 193 in advanced MTAP-null solid tumors
jRCT2041220005Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of anvumetostat in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), biliary cancer and 4 more (14 arms), sponsored by Amgen. Primary endpoints: Number of participants who experience a dose-limiting toxicity, Number of participants who experience a treatment-emergent adverse event and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)biliary cancerhead and neck squamous cell carcinoma (HNSCC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2041220005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220005.